AVI BioPharma to Present Company Overview at the 14th Annual BIO CEO & Investor ConferenceAVI BioPharma, a developer of RNA-based therapeutics, announced today that Chris Garabedian, AVI's president and CEO, will present a company overview at 9:30 a.m. EST on Tuesday, Feb. 14, at the 14th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City.
The presentation will be webcast live under the events section of AVI's website at www.avibio.com and will be archived there following the presentation for 90 days.
Despite Flat Budget, NIH’s TRND Program Tries to Spark Interest in Rare and Neglected DiseasesWith 14 approved programs in total, TRND has progressed two into clinical development. For the past two years NIH has been trying to double its funds for developing orphan drugs. But the FY 2012 budget offered more of the same, as in the same $24 million of annual funding set aside for NIH’s Therapeutics for Rare and Neglected Diseases (TRND) program since its creation in 2009. The institute had sought $50 million for TRND this year and last.
Important Advocacy Webinar: PDUFA ReauthorizationAs PPMD heads into another year advocating in Washington, we encourage all members of our community to learn more about drug development and the FDA. GSK's Clinical Development Plan for DuchenneGSK has released comprehensive details their four controlled clinical studies to evaluate the effect of the investigational medicine GSK2402968 (GSK’968), formerly known as PRO051, in boys with Duchenne, who have a dystrophin gene mutation amenable to an exon 51 skip. |
 
 The Grand Canyon? Hiking? January 30, 2011 | Read More  
|
